-
Mashup Score: 7
Purpose: We describe the impact of screening on outcomes of patients diagnosed with hepatocellular carcinoma (HCC) in an urban safety-net healthcare system compared to a non-screened cohort diagnosed with HCC. Methods: Patients diagnosed with HCC at John Peter Smith Health Network were identified by querying the hospital tumor registry and allocated to the screened cohort if they had undergone any liver imaging within one year prior to HCC diagnosis, while the remainder were allocated to the non-screened cohort. Kaplan–Meier methods and log-rank tests were used to compare 3-year survival curves from an index date of HCC diagnosis. Cox proportional hazard models were used to calculate unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). The Duffy adjustment was used to address lead-time bias. Results: A total of 158 patients were included (n = 53 screened, n = 105 non-screened). The median overall survival (OS) for the screened cohort was 19.0 months (95% CI:
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma - 10 day(s) ago
Survival after sorafenib initiation in newly diagnosed Medicare beneficiaries with hepatocellular carcinoma (HCC) is exceptionally short, suggesting that trial results are not generalizable to all HCC patients. The downsides of sorafenib use—high …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Therapeutic Potential of Ceramide in Cancer Treatment-PDF - 16 day(s) ago
Gentisic Acid, a Quinonoid Aspirin Metabolite in Cancer Prevention and Treatment. New Horizons in Management of Brain Tumors and Systemic
Source: www.boffinaccess.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16ASCO GI Symposium - reasons to attend - 2 month(s) ago
For more information, visit http://www.asco.org/
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16ASCO GI Symposium - reasons to attend - 2 month(s) ago
For more information, visit http://www.asco.org/
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
PURPOSE Systemic therapy with atezolizumab and bevacizumab can extend life for patients with advanced hepatocellular carcinoma (HCC). However, there is substantial variability in response to therapy and overall survival. Although current prognostic models have been validated in HCC, they primarily consider covariates that may be reflective of the severity of the underlying liver disease of patients with HCC. We developed and internally validated a classification and regression tree (CART) to identify patient characteristics associated with risks of early mortality, at or before 6 months from treatment initiation. METHODS This retrospective cohort study used the nationwide Flatiron Health electronic health record–derived deidentified database and included patients with a diagnosis of HCC after January 1, 2020, who received initial systemic therapy with atezolizumab and bevacizumab. CART was developed from available baseline clinical and demographic information to predict mortality withi
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20
The American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 31 to June 4, 2024, featuring cutting-edge research on treating hepatocellular carcinoma (HCC) in the subsequent-line setting. In this article, Timothy J. Brown, MD, MSCE, assistant professor of medicine at the University of Texas Southwestern Medical Center, discusses subsequent-line treatments for HCC that were presented at ASCO 2024.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Dr. Timothy Brown: Advancing GI Cancer Treatment Through Research Excellence | Docwire News - 4 month(s) ago
Dr. Timothy Brown speaks about his career and his passion for gastrointestinal oncology research and patient care.
Source: docwirenews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Promise of Wearable Physical Activity Monitors in Oncology Practice - 7 month(s) ago
Commercially available physical activity monitors provide clinicians an opportunity to obtain oncology patient health measures to an unprecedented degree. These devices can provide objective and quantifiable measures of physical activity, which are not …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1California Consumer Privacy Act (CCPA) - 8 month(s) ago
Updated on March 13, 2024 The California Consumer Privacy Act of 2018 (CCPA) gives consumers more control over the personal information that businesses collect about them and the CCPA regulations
Source: oag.ca.govCategories: General Medicine News, Hem/OncsTweet
Proud to share my first senior author research paper “Impact of Screening on Mortality for Patients Diagnosed with Hepatocellular Carcinoma in a Safety-Net Healthcare System: An Opportunity for Addressing Disparities” https://t.co/xfw7YlTLm3